Evrenzo 20 Mg/ 50 Mg/ 70 Mg/ 100 Mg/ 150 Mg 20 mg/ 50 mg/ 70 mg/ 100 mg/ 150 mg Tablet
PDF Leaflet Revision Date: July 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of anaemia in adult patients with chronic kidney disease (CKD).
Dosage (summary)
Oral, three times per week; starting dose 70 mg (under 100 kg) or 100 mg (100 kg and over).
Special Populations
- Elderly
- Hepatic impairment
- Paediatric population
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- CYP2C8 inhibitors (e.g., gemfibrozil)
- Phosphate binders
Contraindications
- Hypersensitivity to roxadustat
- Pregnancy
- Breastfeeding
- Children under 18 years
Common side effects
- Seizures
- Nausea
- Vascular Access Thrombosis (VAT)
- Deep Vein Thrombosis (DVT)
Counselling Points
- Take orally with or without food.
- Do not chew or crush tablets.
- Monitor for signs of infection.
Serious warnings
- Monitor haemoglobin levels to avoid excessive increases.
- Risk of seizures in predisposed patients.
Important Disclaimer
The Evrenzo 20 Mg/ 50 Mg/ 70 Mg/ 100 Mg/ 150 Mg 20 mg/ 50 mg/ 70 mg/ 100 mg/ 150 mg Tablet professional information leaflet below is the property of Astellas Pharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
